5th Aug 2020 07:00
Mereo BioPharma Group plc
Notification of Director Dealing
London and Redwood City, Calif., August 5, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on July 31 2020 Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 10,563 American Depositary Shares (ADSs) at a price of USD 2.85 per ADS.
The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.
1 | Details of the person discharging managerial responsibilities | |||||
a) | Name | Denise Scots-Knight | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Mereo BioPharma Group plc | ||||
b) | LEI | 213800U8JQHIJOS5AS09 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument and identification code | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)
| ||||
b) | Nature of the transaction | PURCHASE | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: volume, Price | |||||
e) | Date of the transaction | 2020-07-31 | ||||
f) | Place of the transaction | XNMS | ||||
Related Shares:
MPH.L